Outcomes Primary and Secondary Outcome Patients in the semaglutide study arm experienced a significantly lower rate of the primary outcome (cardiovascular composite end-point) (6.5% vs 8.0%, HR 0.80 (95% CI 0.72-0.90) No significant difference in rates of cardiac death (HR 0.85, 95% CI 0.71-1.01) however significantly lower rates of heart failure (HR 0.82, 95% CI 0.71-0.96) and all-cause mortality (HR 0.81, 95% CI 0.71-0.93) Adverse Events Rates and types of adverse events were fairly similar between control and intervention groups Permanent premature discontinuation of semaglutide or placebo occurred in 2351 patients (26.7%) in the semaglutide group and 2078 (23.6%) in the placebo group In obese and overweight patients with cardiovascular comorbidities but without diabetes, treatment with weekly semaglutide was superior to placebo in reducing the incidence of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke at a mean follow-up of 39.8 months
This measurement reflects average glucose over the preceding 8-12 weeks and isnt affected by daily fluctuations or single meal choices
(Phase 2 trials are given to groups of 100 to 300 people to determine its safety and efficacy
SVT Nyheter Uppsala tog med sig bilder p tre svenska nu levande konstnrer: Lars Lerin, Anna Odell och Ernst Billgren, och lt eleverna gissa vilka de r
The medication works quietly in the background, activating GIP and GLP-1 receptors, slowing gastric emptying, enhancing insulin secretion, and suppressing glucagon
